Abstract The purpose of this study was to develop and validate a virtual immunohistochemistry (vIHC) algorithm capable of predicting Cyclin E1 (CCNE1) protein expression from hematoxylin and eosin (H50) and enhanced sensitivity to WEE1 inhibitors. Conventional IHC requires precious tissue and additional laboratory processing; the ViewsML virtual biomarker platform derived from routinely available H Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4155.
Fuchs et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: